Cell News and Research

RSS

Inovalon announces list of organizations supported through its charitable contributions during 2014

Inovalon Holdings, Inc., a leading technology company providing advanced analytics and data-driven intervention platforms to the healthcare industry, today announced the list of organizations supported through its charitable contributions during 2014.

31 Dec 2014

New therapeutic approach shows potential for treating cancer

Case Western Reserve researchers have identified a two-pronged therapeutic approach that shows great potential for weakening and then defeating cancer cells.

31 Dec 2014

Angel MedFlight employees donate gifts to Westwood Primary School in Phoenix

Employees of Angel MedFlight Worldwide Air Ambulance donated backpacks filled with toys, clothing, food and more to Mrs. Butler's first grade class at Westwood Primary School in Phoenix.

31 Dec 2014

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.

29 Dec 2014

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

Soligenix closes previously announced registered public offering

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.

25 Dec 2014

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Novastem, a leader in regenerative medicine, announces the treatment of its first patient in its study for ischemic stroke at Clinica Santa Clarita.

25 Dec 2014

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

CCG completes $8M in Tax Credits to expand, consolidate healthcare services in Sharon

Commonwealth Cornerstone Group (CCG) today announced the completion of an $8 million New Markets Tax Credits transaction on Tuesday to help fund the expansion and consolidation of healthcare services provided by Primary Health Network (PHN) in Sharon.

25 Dec 2014

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

A team of researchers led by Duke Cancer Institute has identified key events that prompt certain cancer cells to develop resistance to otherwise lethal therapies.

24 Dec 2014

Researchers identify mutations that destabilize DNA structure that turns a gene off

Researchers at the University of Louisville's James Graham Brown Cancer Center have identified for the first time mutations that destabilize a DNA structure that turns a gene off. These mutations occur at four specific sites in what is known as the "hTERT promoter" in more than 75 percent of glioblastomas and melanomas.

24 Dec 2014

Scientists image zinc atoms released by fertilized mammalian egg

Sparks literally fly when a sperm and an egg hit it off. The fertilized mammalian egg releases from its surface billions of zinc atoms in "zinc sparks," one wave after another, found a Northwestern University-led interdisciplinary research team that includes experts from the U.S. Department of Energy's Advanced Photon Source at Argonne National Laboratory.

24 Dec 2014

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue.

24 Dec 2014

Researchers describe key group of small DNA fragments in neurone regulation and maturity

A study led by researchers from the University of Toronto and involving the Centre for Genomic Regulation in Barcelona has described a group of small DNA fragments that are key in neurone regulation and maturity.

24 Dec 2014

Cancer could be broken down by its evolving defense mechanism

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease.

24 Dec 2014

Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.

23 Dec 2014

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati Therapeutics, Inc. today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl.

23 Dec 2014

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., announced that it has executed an agreement with Janssen Pharmaceutica NV, for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.

23 Dec 2014

Cell News and Research

Inovalon announces list of organizations supported through its charitable contributions during 2014

New therapeutic approach shows potential for treating cancer

Angel MedFlight employees donate gifts to Westwood Primary School in Phoenix

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Soligenix closes previously announced registered public offering

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

CCG completes $8M in Tax Credits to expand, consolidate healthcare services in Sharon

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

Researchers identify mutations that destabilize DNA structure that turns a gene off

Scientists image zinc atoms released by fertilized mammalian egg

Patent recognizes peptide that reduces tissue damage

Researchers describe key group of small DNA fragments in neurone regulation and maturity

Cancer could be broken down by its evolving defense mechanism

Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring